Acrivon Therapeutics at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Acrivon Therapeutics brings 2 presentations to ENA 2026 in Barcelona. Its posters show its AP3 phosphoproteomics platform at work in drug discovery and in explaining how drugs act. It reports why the WEE1/PKMYT1 inhibitor ACR-2316 outperforms clinical-stage WRN helicase inhibitors and describes selective oral CDK11 inhibitors that induce complete tumor regression in acute myeloid leukemia models.

Organization	ENA 2026 Attendance
Acrivon Therapeutics Watertown, MA
acrivon.com Biotech Clinical-stage oncology company using its AP3 phosphoproteomics platform to discover drugs and match them to responsive patients.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM) Acrivon Predictive Precision Proteomics (AP3)-phosphoproteomics uncovers differential mechanisms driving superior activity of ACR-2316, a novel, clinical-stage WEE1/PKMYT1 inhibitor over clinical-stage WRN helicase inhibitors Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Rapid discovery of selective oral CDK11 inhibitors inducing complete tumor regression in acute myeloid leukemia models using Acrivon Predictive Precision Proteomics (AP3) drug discovery platform Drug design

Organization

ENA 2026 Attendance

Acrivon Therapeutics

Watertown, MA

acrivon.com

Biotech

Clinical-stage oncology company using its AP3 phosphoproteomics platform to discover drugs and match them to responsive patients.

Poster

Thu Nov 19
9:30–10am
1–3pm
4:30–5pm

Part of Poster session: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)

Acrivon Predictive Precision Proteomics (AP3)-phosphoproteomics uncovers differential mechanisms driving superior activity of ACR-2316, a novel, clinical-stage WEE1/PKMYT1 inhibitor over clinical-stage WRN helicase inhibitors

Targeted agents